Today, Owl Cameras announced the company has attracted $10M in new funding, an expansion to their previously announced Series A round. The Series A1 Round was led by Canvas Ventures who invested alongside many who participated in the company’s Series A. This additional investment brings the company’s total venture funding to $28M. [Read more…] about Owl Car Cam Raises $10M in Funding to Expand Production
Focus on Revolutionising the Global Wellbeing and Digital HealthCare Markets
BioBeats, the leader in digital health and artificial intelligence, recently closed a £2.4M funding round led by Oxford Sciences Innovation (OSI), White Cloud and IQ Capital. The new investment will support the company as they focus on delivering their cutting-edge wellness solutions to a global audience.
BioBeats creates evidence-based wellbeing products that help transform people’s lives for the better. Through harnessing user data, artificial intelligence, and human insight, BioBeats provides an ever-improving cycle of evidence-based interventions, finding patterns that link stress to health risks and physical outcomes.
Since 2013, BioBeats has conducted a number of successful clinical trials with BUPA, AXA, and the Center for Digital Economy at the University of Surrey. The trials have been focused on gathering proof of the efficacy and feasibility of BioBeats workforce wellbeing management platform. The team subsequently won two UK government awards through InnovateUK (as part of the IC Tomorrow programme) for clinical excellence and adaptive media innovation. The company is also currently one of the world leaders in the IP space with academic validation published in the Frontiers of Human Neuroscience Journal in January 2017.
In 2015, together with AXA and BNP Paribas, BioBeats conducted the largest UK focused pilot of employee wellbeing. Using their proprietary AI technologies and their BioBase smartphone app, BioBeats was able to assess employee stress in real-time using wearable devices. Since successful completion of the pilot, the company has built their wearable solution, a secure API, and a cloud platform ready to scale.
Speaking about the raise, Dr. David Plans, Founder and CSO of BioBeats, said: “For BioBeats, our vision is to disrupt the way stress is viewed and treated on a global scale. Our approach focuses on challenging the conventional approach to addressing the pandemic of stress and its relation to mental health, cardiovascular disease, and other poor health outcomes; we are truly at a turning point in the digital health revolution, and this latest round of funding will help us achieve remarkable advances for our platform.”
“We’re immensely proud to be supporting the BioBeats team, both because the team is unparalleled in its vision and capability, but also because the company is addressing one of the biggest challenges of our time,” stated Lilly Bussmann, Principal at OSI. “Mental health is the biggest cause of disability-adjusted life years across any non-communicable disease worldwide. And yet, due to the complexity of the problem at hand, few of the analytics and intervention tools needed for transformative change have emerged. This is where BioBeats comes in and hence why we’re so thrilled to be working with the team.”
With the support of OSI, BioBeats will embark on a new era of innovation and experimentation. This year, both Dr. David Plans and Dr. Davide Morelli, two of the company’s founders, will begin their doctoral work within Experimental Psychology and Biomedical Engineering under the supervision of academic groups at Oxford University. This new chapter will bring BioBeats’ existing technology and research to a new level of peer review and validation.
BioBeats groundbreaking app, BioBase, offers users the ability to track, manage and control stress. It is currently the only wellbeing and stress management app on the market to do so. The company’s offering not only allows users to track stress levels, but also educates users on how to reduce stress and helps them identify their personal stress triggers.
Plans concluded, “BioBeats has a distinct competitive advantage in the marketplace, we are the only science-backed technology focusing on stress management and wellness from the AI perspective, and we have been doing this successfully longer than anyone else. With this investment, we aim to expand our reach and product capabilities, and ultimately provide evidence that predictive analytics and AI could change mental health care delivery globally.”
Toronto-based start-up Qindom has secured seed round funding for its quantum intelligence initiatives that aim for landing quantum computing in industry application. The $2 million USD financing is led by an individual investor, who is one of the early LPs of Sequoia Capital.
“The investment is significant for a start-up in quantum computing and will serve for Qindom’s strategic development toward future growth. We look forward to helping businesses leverage the power of quantum intelligence to navigate and transform in the coming quantum computing era,” said Yao Wang, Co-Founder of Qindom, a serial entrepreneur who previously served for Alibaba Group.
Qindom, based in Toronto, Canada, was founded in January 2018 as a quantum intelligence (QI) research and application service provider. The company’s open platform and intellectual properties are designed for applying quantum computing to revolutionize fundamental algorithms and models for combinatorial optimization problems, and for realizing quantum intelligence in real-world industry practices.
Qindom has gathered the most brilliant minds of our times from various academic fields and industries. The team is composed of world-leading scientists, industry experts and experienced entrepreneurs. 90% of Qindom’s R&D team are professors and have PhDs of cross-disciplinary backgrounds in Mathematics, Physics, Quantum Computing, Optimization, Machine Learning, Data Science, etc.
Qindom’s QI solution applies quantum computing technologies to address complex combinatorial optimization problems in various industrial scenarios. Quantum features, which include superposition state, entanglement effect, and tunneling effect, are combined with classic computing technologies under Qindom’s proprietary research and development. AI is among the areas where complex optimization problems locate. By reconstructing AI with quantum computing technologies in research and applications, QI will achieve parallel computing and fair sampling and boost the performance of all algorithms and models to the next level.
Qindom works closely with leading research institutes in North America and forms strategic partnerships with multiple industry leaders in Canada, China, and United States. Qindom’s clients and partners benefit from its RD&E services, cloud-based QI platform, and industry solutions. The company’s QI application currently constitutes prediction in financial investment, route planning in logistics, recommendation in e-commerce, and customer churn prevention in telecommunication and insurance, etc. Qindom’s current prototypes include a quantitative stock prediction and trading strategy system in FinTech, a customer churn and retention prediction and optimization solution for telecommunication, and a reserve requirement rate (RRR) optimization model for credit and risk control in banking.
“Qindom’s QI solution will apply quantum computing technologies to potentially address complex optimization problems in a wide array of industry application scenarios,” commented by Yao. “For the moment, we will focus on RD&E of our premier QI technology, build up the architecture of our QI-based cloud platform, and continue to seek business partners to expand Qindom’s QI community.”
Qindom is a premier Quantum Intelligence (QI) research and solution service provider. The company is set to provide sustainable QI solutions and pioneer industry standards. Its proprietary RD&E is designed for applying quantum computing to revolutionize fundamental algorithms and models and realizing QI in real-world industry practices.
Additional information may be found at http://qindom.com
Sansoro Health, Inc., a pioneer in data integration for health care, today announced an $8 million Series B investment led by LRVHealth, with participation from existing investors Bain Capital Ventures and Healthy Ventures. The funding will accelerate the adoption and evolution of its Emissary® software platform, which facilitates robust integration of digital health applications with electronic health records (EHRs). Sansoro Health has raised a total of $14.5 million.
Lack of EHR interoperability poses a significant challenge contributing to rising costs and inefficient care, while hindering digital health innovation. Only six percent of health care providers say they can effectively access EHRs between different systems, according to a study by KLAS Research. Underscoring the importance of these challenges, the recent announcement by the Centers for Medicare and Medicaid Services (CMS) aligns payment and reporting requirements with greater interoperability. Further, CMS is emphasizing the use of application programming interface (API) technology as a way to solve these problems without requiring special effort on the part of providers. Sansoro Health meets these challenges today by offering health IT innovators turnkey API integration with major EHR systems.
“We are fortunate to have LRVHealth as a partner to support our vision to unleash the power of health data,” said Jeremy Edes Pierotti, CEO of Sansoro Health. “LRVHealth’s team and its network of health care industry investors will help us grow even faster and build on our success in delivering a practical, efficient and scalable solution for EHR integration.”
“Sharing data between disparate EHR systems remains a major challenge – one that I’ve seen firsthand and that strategic investors in our collaborative investing platform deal with every day,” said Keith J. Figlioli, general partner at LRVHealth. “When providers, payers and patients are able to move and integrate data across many sources, health care technology becomes infinitely more valuable for everyone, and that’s why we invested in Sansoro Health. Its technology has had a tremendous impact already, and we’re looking forward to extending and accelerating that impact.”
“As EHR adoption catalyzes an entirely new digital health IT market, the need for Sansoro Health’s data integration platform is increasingly critical,” said Yumin Choi, managing director of Bain Capital Ventures. “Current data integration solutions are broken. They’re slow, limited in scope and challenging to manage. By offering robust integration that dramatically and consistently reduces implementation time and effort, we believe Sansoro Health has both the product and leadership to dominate in the multi-billion-dollar digital health connectivity market.”
Giving Digital Health Partners Freedom to Innovate
Advanced health IT applications like telehealth, precision medicine, and patient engagement require true interoperability to operate efficiently at scale. Sansoro Health’s Emissary platform removes the biggest barriers to high performance today by liberating health data with a powerful universal API. This allows health IT innovators to spend less time on the tedious work of integration and focus more on developing transformative products.
Sansoro Health estimates its digital health partners reduce integration efforts by as much as 75 percent. In addition, they deploy applications 80 percent faster and dramatically reduce the burden on hospital systems’ IT staff. One customer reports that Emissary has reduced implementation time by over 200 hours per hospital. Another says Sansoro Health’s technology makes its pharmacists 200 percent more productive.
As part of LRVHealth’s investment, Keith Figlioli will join Sansoro Health’s Board of Directors, which also includes Yumin Choi, Managing Director of Bain Capital Ventures, and Omar Hussain, CEO of Placester and former Imprivata CEO.
About Sansoro Health
Sansoro Health solves health IT’s most pressing challenge today – achieving secure, seamless data exchange between electronic health records (EHRs) and leading-edge clinical and administrative applications. Health IT innovators leverage Emissary®, Sansoro Health’s award-winning software platform, to install swiftly, deliver robust functionality and slash integration resources. Sansoro Health believes deeply in the power of innovation and collaboration to usher in the next generation of health care. To learn how Emissary creates agile integration, visit sansorohealth.com
Concourse Global, an online platform for education institutions that brings together college guidance counselors and artificial intelligence to match and connect international students with higher education opportunities, today announced that it has completed the initial closing of a staged $2 million in seed funding led by Colle Capital. Other investors include A-Star Education, Third Kind VC, LearnStart, and Jay Varkey, Group Executive Director of GEMS Education.
As graduating high school students around the world seek an edge in a globalizing economy, they are increasingly crossing borders for their higher education. International student numbers have quadrupled since 1990, and this is expected to double again in the next decade. It is a $200 billion dollar industry, and institutions worldwide compete fiercely to attract the right students for their programs.
Although rapidly evolving, the industry does not operate efficiently. High school counselors are overworked, under-resourced, and not always in a position to research the best options for every one of their students. “We have built the industry’s first matching technology platform that enables high schools and universities to collaborate to find opportunities for students,” said Joe Morrison, Concourse CEO. “Our platform enables counselors to use their knowledge and close relationships with their students to guide the recommendation process and manage interactions with university admissions officers, so that students receive thoughtful, curated offers from interested institutions, not spam.”
A-Star Education and GEMS Education are large international education companies, each operating a global portfolio of K-12 schools. “We are excited to be partnering with our colleagues at Colle Capital on this transaction. Concourse is a unique platform that will bring value and opportunity to the K-12 space,” said Jay Varkey, GEMS Education Group Executive Director.
Brian Rogove, A-Star Education Founder and CEO said “We invested in Concourse because it fills an important niche in the portfolio of institutions and services that we offer our students, and provides a much-needed technology platform in a rapidly growing market.”
Concourse plans to use the new funding to expand and further develop their AI based matching technology to increase opportunities for discovery and engagement between students, high school counselors, and universities.
“AI and marketplaces are at the core of our investment strategy. We are excited to see Concourse apply their deep domain knowledge and technical expertise to the international education market, one of the world’s largest export industries, and to have assembled such a strong industry-specific investor group,” said Victoria Grace, Colle Capital Founding Partner.
Concourse aims to make higher education more globally accessible and affordable by lowering the cost of enrollment management and enabling universities to better plan and allocate their capacity. “This is the future of student recruitment,” said Joe Morrison. “There is a program out there for every student, and a student for every program. Concourse is where they will find each other.”
About Concourse Global
Concourse Global Enrollment, Inc. is a Brooklyn based education technology company with the mission of making higher education more globally accessible. Concourse harnesses the collective power of human advisors and artificial intelligence to provide guidance and support to students in their higher education journey, and enables higher education institutions to discover and welcome those students in accordance with their enrollment capacity and constraints.